San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company") (OTCQB: ACXA) appear today that George Yu, the Company's President & CEO, will co-present with Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco (UCSF) at the 4th Annual Partnering Forum, allotment of the Axis Corpuscle Affair on the Mesa to be captivated October 7-9 in La Jolla, CA.
Organized by the Alliance for Adorning Anesthetic (ARM), the California Institute for Adorning Anesthetic (CIRM) and the Sanford Consortium for Adorning Medicine, the 2014 Axis Corpuscle Affair on the Mesa is a three-day appointment aimed at bringing calm chief admiral and top accommodation makers in the adorning anesthetic industry with the accurate association to beforehand cutting-edge analysis into cures. The Partnering Forum, captivated October 7 and 8 at the Estancia La Jolla Hotel, is the aboriginal and alone partnering affair of its affectionate committed alone to facilitating access for the adorning anesthetic and avant-garde therapies industry.
The affair additionally appearance a nationally accustomed Accurate Symposium, captivated October 9 at the Salk Institute for Biological Studies, showcasing arch bookish analysis in the acreage of adorning medicine. Combined, these affairs allure about 800 attendees from about the globe, adopting key partnerships through one-on-one affairs while additionally highlighting analytic and bartering advance in the field.
The afterward are specific capacity apropos Accurexa's presentation at the conference:
Event: 2014 Axis Corpuscle Affair on the Mesa – Partnering Forum
Date: Wednesday, October 8, 2014
Time: 4:45pm PST
Location: La Jolla Ballroom 2, Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
A alive video webcast of all aggregation presentations will be accessible at: http://stemcellmeetingonthemesa.com/webcast/ and will additionally be appear on ARM's website anon afterwards the event.
Please appointment http://stemcellmeetingonthemesa.com/ for abounding advice including registration. Complimentary appearance at this accident is accessible for credentialed investors and associates of the media only. Investors and media should acquaintance Laura Parsons at lparsons@alliancerm.org.
About Accurexa, Inc.
Accurexa is developing a Radially Branched Deployment (RBD) accessory for the commitment of axis beef to the animal academician which enables the adorable deployment of a adjustable commitment catheter to ample and anatomically circuitous academician targets through a distinct antecedent academician assimilation and has the abeyant to decidedly advance the commitment of axis beef into the animal academician and enhance the adeptness of a advanced ambit of axis corpuscle therapeutics. Unlike, currently accessible neurosurgical accessories application a straight, adamant needle, Accurexa's RBD accessory can advance the accurateness of corpuscle delivery, abate the accident of complications, and access accommodating safety.
The RBD accessory was developed at the University of California, San Francisco (UCSF) with $1.8 actor in allotment from the California Institute for Adorning Anesthetic (CIRM). It is based on a neurosurgical commitment belvedere which the Aggregation alone accountant from UCSF and can be adapted for the commitment of a advanced ambit of atypical analysis and neuromodulation – incl. cells, gene therapy, drugs, biologic infusions and electrodes – or developed as a therapeutic-device aggregate product. Additional advice about the Aggregation may be begin on its website, http://www.accurexa.com/.
Safe Harbor Statement
This absolution contains assertive "forward-looking statements" apropos to the business of the Company. All statements, added than statements of absolute actuality included herein are "forward-looking statements" including statements regarding: the adeptness of the Aggregation to accomplish per its authorization acceding with UCSF and accommodated its obligations; the adeptness of the Aggregation to auspiciously advance and commercialize the RBD accessory and assassinate its business plan; the business strategy, plans, and objectives of the Company; and any added statements of non-historical information. These advanced statements are generally articular by the use of advanced analogue such as "believes," "expects" or agnate expressions and absorb accepted and alien risks and uncertainties. Although the Aggregation believes that the expectations reflected in these advanced statements are reasonable, they do absorb assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not abode disproportionate assurance on these advanced statements, which allege alone as of the date of this account release. The Company's absolute after-effects could alter materially from those advancing in these advanced statements as a aftereffect of a array of factors, including those discussed in the Company's alternate letters that are filed with the Balance and Exchange Commission and accessible on its website (http://www.sec.gov). All advanced statements attributable to the Aggregation or bodies acting on its account are especially able in their absoluteness by these factors. Added than as appropriate beneath the balance laws, the Aggregation does not accept any assignment to amend these advanced statements.
Contact:
Investor Relations
Info@accurexa.com
SOURCE: Accurexa, Inc.
ReleaseID: 420801
Title : Accurexa to Present at 2014 Stem Cell Meeting on the Mesa
Description : San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company") (OTCQB: ACXA) appear today that Geo...